Bottom line
MFCRX vs VPMCX: the short answer
MFCRX (Meridian Contrarian Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds.
But VPMCX is far broader, holding 173 positions to 79 for MFCRX, so beyond the top names it adds exposure MFCRX doesn't have.
Updated Nov 19, 2026
MFCRX vs VPMCX side by side
| MFCRX | VPMCX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Meridian | Vanguard |
| Category | Large Blend | Large Blend |
| Expense ratio | — | 0.35% |
| Annual cost per $10k | — | $35 |
| 10-yr cost on $10k (prospectus) | — | $443 |
| Max front load | — | 0% |
| 12b-1 fee | — | 0% |
| 1-yr return | — | +29.9% |
| 5-yr return (annualized) | — | +14.3% |
| 10-yr return (annualized) | — | +15.2% |
| Best quarter | — | +17.3% |
| Worst quarter | — | −20.2% |
| Net assets (fund) | $679.5M | $96.1B |
| Number of holdings | 79 | 173 |
| Portfolio turnover | 53% | 11% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MFCRX and VPMCX share none of their top holdings.
MFCRX top 10
- Goldman Sachs Trust — 7.61%
- Texas Capital Bancshares Inc — 2.59%
- Envista Holdings Corp — 2.57%
- Regal Rexnord Corp — 2.44%
- First Citizens Bancshares Inc — 2.42%
- Stit Govt And Agency Inst — 2.37%
- Vse Corp — 2.10%
- Pdf Solutions Inc — 2.07%
- Blackberry Ltd — 2.05%
- Dollar Tree Inc — 1.96%
VPMCX top 10
- Micron Technology Inc — 13.50%
- Intel Corp — 6.80%
- Eli Lilly & Co — 6.76%
- KLA Corp — 3.85%
- Alphabet Inc — 3.52%
- AstraZeneca PLC — 2.35%
- NVIDIA Corp — 2.33%
- Amazon.com Inc — 2.05%
- Tesla Inc — 1.89%
- Biogen Inc — 1.88%
FAQ
What is the difference between MFCRX and VPMCX?
MFCRX (Meridian Contrarian Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds. But VPMCX is far broader, holding 173 positions to 79 for MFCRX, so beyond the top names it adds exposure MFCRX doesn't have.
Should I own both MFCRX and VPMCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.